A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration

Gut

Volumn 64, Issue 8, 2015, Pages 1296-1302

  King, Lindsay Y ^a   Canasto Chibuque, Claudia ^b   Johnson, Kara B ^a   Yip, Shun ^b   Chen, Xintong ^b   Kojima, Kensuke ^b   Deshmukh, Manjeet ^b   Venkatesh, Anu ^b   Tan, Poh Seng ^b,c   Sun, Xiaochen ^b   Villanueva, Augusto ^d   Sangiovanni, Angelo ^e   Nair, Venugopalan ^a   Mahajan, Milind ^a   Kobayashi, Masahiro ^f   Kumada, Hiromitsu ^f   Iavarone, Massimo ^e   Colombo, Massimo ^e   Fiel, Maria Isabel ^a   Friedman, Scott L ^b   Llovet, Josep M ^b,g,h   Chung, Raymond T ^a   Hoshida, Yujin ^b   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

^f TORANOMON HOSPITAL   (Japan)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; VIRUS RNA;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD PUGH SCORE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INCIDENCE; INTERMEDIATE RISK POPULATION; ITALIAN (CITIZEN); LIVER CELL CARCINOMA; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; THROMBOCYTE COUNT; UNITED STATES; COMPLICATION; DISEASE COURSE; FOLLOW UP; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; VIROLOGY;

DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; UNITED STATES;

EID: 84940381737     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307862     Document Type: Article

References (46)

1. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7:425-36.
2. Lozano R, Naghavi M, Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-128.
3. Jacobson IM, Davis GL, El-Serag H, et al. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8:924-33; quiz e117.
4. Zalesak M, Francis K, Gedeon A., et al. Current and future disease progression of the chronic HCV population in the United States. PLoS ONE 2013; 8:e63959.
5. Ly KN, Xing J, Klevens R.M., et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271-8.
6. Myers RP, Krajden M, Bilodeau M., et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol 2014; 28:243-50.
7. van der Meer AJ, Veldt BJ, Feld J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama 2012; 308:2584-93.
8. Singh S, Singh PP, Roberts L.R., et al. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014; 11:45-54.
9. Chung RT, Baumert TF Curing chronic hepatitis C - the arc of a medical triumph. N Engl J Med 2014; 370:1576-8.
10. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-27.
11. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245-55.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-2.
13. EASL-EORTC. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-43.
14. Davila JA, Henderson L, Kramer J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154:85-93.
15. Smith JO, Sterling RK Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009; 30:557-76.
16. Hoshida Y, Fuchs BC, Tanabe KK Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets 2012; 12:1129-59.
17. Nault JC, De Reynies A, Villanueva A, et al A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 2013; 145:176-87.
18. Hoshida Y, Villanueva A, Kobayashi M., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359:1995-2004.
19. Hoshida Y, Villanueva A, Sangiovanni A., et al. Prognostic gene-expression signature for patients with Hepatitis C-related early-stage cirrhosis. Gastroenterology 2013; 144:1024-30.
20. Villanueva A, Hoshida Y, Battiston C., et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140:1501-12. e2.
21. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675-80.
22. Sangiovanni A, Del Ninno E, Fasani P, et al Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126:1005-14.
23. Ishak K, Baptista A, Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
24. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20(1 Pt 1): 15-20.
25. Hoshida Y. Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment. PLoS ONE 2010; 5:e15543.
26. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
27. Beck JR, Pauker SG, Gottlieb J.E., et al. A convenient approximation of life expectancy (the "DEALE" II. Use in medical decision-making. Am J Med 1982; 73: 889-97.
28. Kamath PS, Kim WR The model for end-stage liver disease (MELD). Hepatology 2007; 45:797-805.
29. Singal AG, Mukherjee A, Elmunzer B.J., et al. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 2013; 108:1723-30.
30. El-Serag H.B., Kanwal F, Davila J.A., et al. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 2014; 146:1249-55. e1.
31. van der Meer AJ, Hansen BE, Fattovich G, et al Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut 2015; 64:322-31.
32. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158:807-20.
33. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med 2010; 2:14ps2.
34. Reis PP, Waldron L, Goswami R.S., et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 2011; 11:46.
35. Northcott PA, Shih DJ, Remke M, et al Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 2012; 123:615-26.
36. Kojima K, April C, Canasto-Chibuque C, et al. Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS ONE 2014; 9:e86961.
37. Vogelstein B, Papadopoulos N, Velculescu V.E., et al. Cancer genome landscapes. Science 2013; 339:1546-58.
38. Lok AS, Everhart JE, Wright E.C., et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140:840-9; quiz e12.
39. Bruix J, Poynard T, Colombo M., et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011; 140:1990-9.
40. Okita K, Izumi N, Matsui O., et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol 2014.
41. Lippman SM, Klein EA, Goodman P.J., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39-51.
42. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008; 14:5984-93.
43. Fuchs BC, Hoshida Y, Fujii T., et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 2014; 59:1577-90.
44. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; 31:1806-14.
45. Wong KF, Xu Z, Chen J., et al. Circulating markers for prognosis of hepatocellular carcinoma. Expert Opin Med Diagn 2013; 7:319-29.
46. Dufour JF. Modern hepatomancy. Gastroenterology 2013; 144:876-8.